Resveratrol-Loaded Microsponge as a Novel Biodegradable Carrier for Dry Powder Inhaler: A New Strategy in Lung Delivery
- PDF / 568,901 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 40 Downloads / 145 Views
Resveratrol-Loaded Microsponge as a Novel Biodegradable Carrier for Dry Powder Inhaler: A New Strategy in Lung Delivery Ashwin J. Mali 1
&
Anamika Rokade 1 & Ravindra Kamble 1 & Atmaram Pawar 1 & C. Bothiraja 1
Accepted: 14 October 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract The aim of the present study was to prepare a resveratrol-loaded microsponge-based dry powder inhaler (RES-MS-DPI) using the quasi-emulsion solvent diffusion method and to explore its suitability for pulmonary delivery. The prepared microsponges were evaluated for physicochemical properties. Additionally, an in vitro lung deposition study was performed using an Andersen cascade impactor (ACI), while in vivo performance was studied by intratracheal administration. The optimized porous and spherical RES-MS showed particle size, surface charge, entrapment efficiency, mass median aerodynamic diameter (MMAD) and fine particle fraction (FPF) of 2.499 ± 0.56 μm, −25.34 mV, 89.45 ± 0.23%, 2.13 ± 0.21 μm and 48.54 ± 0.25%, respectively, with controlled release. Further, in vitro and in vivo studies of RES-MS showed a twofold improvement in the FPF, and 4.4-, 14.12- and 1.94-fold improvement in the area under the curve (AUC), mean residence time (MRT) and Cmax. The RES-MS exhibited higher aerosolization and lung deposition. Keywords Microsponge . Resveratrol . Poly(lactic-co-glycolic acid) . Dry powder inhaler . Andersen cascade impactor . Fine particle fraction
1 Introduction Lung cancer is one of the leading causes of morbidity and mortality among all malignancies worldwide. The major causes of lung cancer are air pollution, smoke and ionizing radiation. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 80–85% of all types of lung cancers, and is the most frequently seen in elderly patients. In addition, secondary lung cancer due to metastatic outgrowth is reported at alarming rates, as only 16% of cases are detected in the early stages, resulting in only a 5% survival rate [1–5]. To a very great extent, lung cancer is treated by conventional therapy modalities such as surgery, radiation and chemotherapy. Various clinical trials are also assessing new methods for the effective treatment of cancer. However, oral and parenteral routes are generally preferred for administration of chemotherapeutics, leading to unwanted
* Ashwin J. Mali [email protected] 1
Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, Maharashtra 411038, India
exposure of the drug to the whole body. This also leads to a subtherapeutic concentration of the drug at the target site, with unwanted drug exposure to normal cells and tissues. Moreover, acquired resistance to the anticancer agent is also observed due to the apoptotic mechanism in NSCLC cell lines. Maximum drug concentration in the solid tumour is the main concern for achieving optimal anticancer activity. Thus there is an urgent need to explore more effective treatment moda
Data Loading...
